Evoq Remedies Limited

543500

INE0JVD01011

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 06:48:32 25/06/2024 BST			5-day change	1st Jan Change
10.66 ^INR	+3.39%		+12.09%	-27.73%

06-11	Evoq Remedies Limited announced that it expects to receive INR 192.1 million in funding	CI
05-27	Evoq Remedies Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Evoq Remedies Limited Approves Resignation of Tarunkumar Patel as Director

May 25, 2023 at 02:29 pm

Evoq Remedies Limited at its board of directors meeting held on May 25, 2023, approved the resignation of Mr. Tarunkumar Patel as a Director of the Company with effect from 25th May, 2023.

Latest news about Evoq Remedies Limited

Evoq Remedies Limited announced that it expects to receive INR 192.1 million in funding	06-10	CI
Evoq Remedies Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-27	CI
Evoq Remedies Limited Announces Resignation of Bhumishth Patel as Managing Director	02-03	CI
Evoq Remedies Limited Approves Appointment of Gitika Mishra as Company Secretary and Compliance Officer	02-03	CI
Evoq Remedies Limited announced that it expects to receive INR 226 million in funding	01-21	CI
Evoq Remedies Bags Contract Worth INR1.4 Billion	01-10	MT
Evoq Remedies Limited Receives Export Order of INR 1,360 Million from the Marlexx Pharma Inc	01-10	CI
Evoq Remedies Limited Reports Earnings Results for the Half Year Ended September 30, 2023	11-10	CI
Evoq Remedies Limited Announces Resignation of Directors	11/09/23	CI
Evoq Remedies Limited Announces Resignation of Parth Kamdar as Company Secretary and Compliance Officer, Effective From 12 July, 2023	13/06/23	CI
Evoq Remedies Limited Approves Resignation of Tarunkumar Patel as Director	25/05/23	CI
Evoq Remedies Limited Reports Earnings Results for the Full Year Ended March 31, 2023	25/05/23	CI
7,210,000 Equity Shares of Evoq Remedies Limited are subject to a Lock-Up Agreement Ending on 4-APR-2023.	03/04/23	CI
Evoq Remedies Limited Announces Resignation of Bhumishth Patel as Chairman and Managing Director	31/03/23	CI
Evoq Remedies Limited Reports Earnings Results for the Half Year Ended September 30, 2022	07/11/22	CI
Evoq Remedies Limited Appoints Parth Kamdar as Company Secretary and Compliance Officer	03/09/22	CI
Evoq Remedies Limited Approves Resignation of Tej Hanj from the Post of Company Secretary and Compliance Officer of the Company	03/09/22	CI
Evoq Remedies Limited has completed an IPO in the amount of INR 97.2 million.	25/03/22	CI
Evoq Remedies Limited has filed an IPO in the amount of INR 97.2 million.	24/02/22	CI

EVOQ Remedies Limited is an India-based company, which is a manufacturer and supplier of pharmaceutical products. The Company is engaged in the pharmaceutical business involving marketing, trading, and distribution of a range of pharmaceutical formulation products, such as antibiotic drugs, anti-malarial drugs, anti-allergic and cold drugs, analgesic/antipyretic and anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium, multivitamins, antioxidants, and injections. It offers a range of pharmaceutical formulation products, of which around 120 products are marketed by the Company under its own brand name. It also deals in the trading of active pharmaceutical ingredients (APIs). Its products include Abacavir Sulphate, Acetazolamide, Acyclovir, Adefovir Dipivoxil Allylestrenole, Alpha Beta Arteether, Alpha Lipoic Acid, Alprazolam , Amoxycillin Trihydrate, Ampicillin Trihydrate, and more.

Sector

Pharmaceuticals

Calendar

05/11/2024 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EVOQ REMEDIES LIMITED	-27.73%	1.68M
ELI LILLY AND COMPANY	+52.70%	801B
NOVO NORDISK A/S	+41.58%	631B
JOHNSON & JOHNSON	-4.86%	359B
MERCK & CO., INC.	+21.96%	337B
ABBVIE INC.	+11.47%	305B
ASTRAZENECA PLC	+17.72%	245B
ROCHE HOLDING AG	+4.46%	231B
NOVARTIS AG	+13.13%	219B
AMGEN INC.	+10.46%	171B